Heron Therapeutics COO exercises 11,769 RSUs
Heron Therapeutics (HRTX) Chief Operating Officer Mark Earl Hensley reported the vesting and conversion of 11,769 Restricted Stock Units into 11,769 shares of common stock on July 31, 2026.
Rhea-AI Filing Summary
Heron Therapeutics (HRTX) Chief Operating Officer Mark Earl Hensley reported the vesting and conversion of 11,769 Restricted Stock Units into 11,769 shares of common stock on July 31, 2026. His direct common stock holdings increased to 148,539 shares, while 164,776 Restricted Stock Units remain outstanding from a 188,315-unit grant dated January 30, 2026, which vests in 16 equal quarterly installments. Each RSU represents a contingent right to receive one share of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
11,769 shares exercised/converted
Exercise
2 txns
Insider
Hensley Mark Earl
Role
Chief Operating Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units F2 | 11,769 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 11,769 | -- | -- |
Holdings After Transaction:
Restricted Stock Units — 164,776 contracts (Direct);
Common Stock — 148,539 shares (Direct)
Footnotes (2)
- F1. Each restricted stock unit represents a contingent right to receive one share of common stock.
- F2. On January 30, 2026 (the "Date of Grant"), the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments beginning one quarter after the Date of Grant.
Key Figures
RSUs converted to common stock: 11,769 units
Common shares acquired via RSU conversion: 11,769 shares
Common shares held after transaction: 148,539 shares
+3 more
6 metrics
RSUs converted to common stock
11,769 units
Restricted Stock Units converted into common stock on July 31, 2026
Common shares acquired via RSU conversion
11,769 shares
Common Stock received upon RSU conversion on July 31, 2026
Common shares held after transaction
148,539 shares
Direct common stock ownership of Mark Earl Hensley following the reported transactions
RSUs outstanding after transaction
164,776 units
Remaining Restricted Stock Units held after 11,769-unit conversion
Original RSU grant size
188,315 units
Restricted Stock Units granted on January 30, 2026
Vesting schedule installments
16 quarterly installments
RSUs vest in 16 equal quarterly installments beginning one quarter after January 30, 2026
Key Terms
Restricted Stock Units, contingent right, time-based vesting schedule, derivative security
4 terms
Restricted Stock Units financial
"the Reporting Person was granted 188,315 RSUs which vest upon the following time-based vesting schedule"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share of common stock"
time-based vesting schedule financial
"which vest upon the following time-based vesting schedule: the RSUs vest in 16 equal quarterly installments"
derivative security financial
"transaction code M has the description Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Heron Therapeutics (HRTX) report for COO Mark Earl Hensley?
Heron Therapeutics reported that COO Mark Earl Hensley had 11,769 Restricted Stock Units convert into 11,769 shares of common stock on July 31, 2026. This RSU settlement increased his direct common share holdings and reduced his RSU balance by the same number of units.
What are the terms of Mark Hensley’s RSU grant at Heron Therapeutics (HRTX)?
Mark Hensley was granted 188,315 Restricted Stock Units on January 30, 2026. According to the grant terms, these RSUs vest in 16 equal quarterly installments, beginning one quarter after the grant date, with each RSU representing a contingent right to receive one common share.
Was the recent HRTX insider transaction under a Rule 10b5-1 plan?
No. The Form 4 for Heron Therapeutics (HRTX) indicates the Rule 10b5-1 checkbox is not selected, meaning the reported RSU conversion for COO Mark Earl Hensley was not affirmatively reported as executed under a Rule 10b5-1 trading plan.
Did the COO buy or sell Heron Therapeutics (HRTX) stock in the open market?
No open-market purchase or sale is reported. The Form 4 shows only a derivative exercise/conversion, where 11,769 Restricted Stock Units settled into an equal number of common shares. There are no transactions with purchase code “P” or sale code “S” in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
